What Is Mold Inspection

ERMI (Environmental Relative Moldiness Index) and HERTSMI-2 (Health Effects Roster of Type-Specific Formers of Mycotoxins and Inflammagens, second version) are laboratory tests that use DNA-based analysis of settled dust to identify and quantify mold species present in an indoor environment. ERMI evaluates 36 species and generates a comparative moldiness score, while HERTSMI-2 focuses on five species most strongly linked to human biotoxin illness. Both tests serve as objective tools for determining whether indoor fungal contamination has reached levels that may affect occupant health.

Chronic exposure to elevated indoor mold and the mycotoxins some species produce has been associated with persistent inflammatory responses, immune dysregulation, and neurological symptoms that can erode long-term health. The challenge is that conventional air quality tests offer only a snapshot of airborne spore counts at a single moment, making them unreliable for assessing cumulative exposure. ERMI and HERTSMI-2 solve this by analyzing mold DNA fragments embedded in settled dust, which accumulates over time and reflects a more stable picture of what occupants have been breathing.

For individuals concerned with healthspan and longevity, indoor environmental quality ranks alongside diet and sleep as a foundational variable. Undetected mold contamination can drive chronic activation of innate immune pathways, disrupt hormonal signaling, and impair detoxification capacity. Identifying and quantifying the problem is the necessary first step before any remediation or clinical treatment protocol can be effective.

Both tests rely on a molecular technique called mold-specific quantitative polymerase chain reaction (MSQPCR). A dust sample is collected from the indoor environment, and the laboratory extracts DNA from the material. MSQPCR then amplifies and quantifies DNA sequences unique to each target mold species, producing a spore equivalent count for every organism on the panel.

ERMI compares 26 species associated with water-damaged buildings (Group 1) against 10 species commonly found in all environments regardless of water damage (Group 2). The final ERMI score is the difference between the log-transformed sum of Group 1 species and Group 2 species. A higher score indicates greater relative moldiness compared to a reference set of U.S. homes. HERTSMI-2 takes a different approach by scoring only five species: Aspergillus penicillioides, Aspergillus versicolor, Chaetomium globosum, Stachybotrys chartarum, and Wallemia sebi. Each species receives a score based on its spore equivalent concentration, and the five scores are summed. The resulting number is compared against thresholds developed in clinical settings focused on CIRS patients.

Because these tests detect DNA rather than viable spores, they can identify mold contamination even after colonies have dried out or been partially treated. This also means that a positive result does not necessarily indicate active growth, but it does confirm that the building has harbored significant mold populations. Interpreting results requires understanding that DNA persistence in dust varies by species and that a single test represents the cumulative history of the sampling location rather than current air quality alone.

ERMI measures DNA-based spore equivalent concentrations for 36 mold species divided into two groups. Group 1 contains 26 species associated with water-damaged buildings, including Stachybotrys chartarum, Aspergillus versicolor, Chaetomium globosum, and Wallemia sebi. Group 2 contains 10 species found commonly in outdoor and indoor environments regardless of water damage, serving as a baseline reference. The final ERMI score represents the relative abundance of water-damage indicator species compared to common species.

HERTSMI-2 measures spore equivalents for five specific species selected for their association with biotoxin illness: Aspergillus penicillioides, Aspergillus versicolor, Chaetomium globosum, Stachybotrys chartarum, and Wallemia sebi. Each species is scored individually based on its concentration, and the sum produces the total HERTSMI-2 score. This narrower focus makes HERTSMI-2 more targeted toward health risk assessment for individuals with suspected CIRS, while ERMI provides a broader environmental profile.

To obtain a representative sample, avoid vacuuming or mopping the sampling area for at least five days before collection. The goal is to allow dust to accumulate sufficiently so that the DNA extracted reflects the cumulative mold profile of the environment rather than a freshly cleaned surface. If testing a carpeted room, some protocols recommend vacuuming a defined area into a collection cassette rather than using a Swiffer cloth.

Select sampling locations based on where occupants spend the most time, typically the master bedroom and main living area. If you suspect contamination from a specific source such as a basement or bathroom, consider collecting separate samples from those areas in addition to the primary living spaces. Keep windows and doors in their normal state during the days leading up to collection; do not artificially ventilate or seal the space. Follow the laboratory's specific instructions for sealing and shipping the sample, as improper handling can degrade DNA and affect accuracy.

ERMI scores typically range from about negative 10 to positive 20 or higher. Scores below negative 4 are considered low relative moldiness, scores between negative 4 and 0 are moderate, and scores above 0 indicate elevated moldiness compared to the national reference database. However, a single number does not tell the full story; reviewing the individual species breakdown can reveal whether a particularly concerning organism such as Stachybotrys chartarum is present even if the overall score appears moderate.

HERTSMI-2 scores are interpreted against thresholds used in clinical practice. Scores below 11 are generally considered safe for individuals with known mold sensitivity or CIRS. Scores between 11 and 15 suggest moderate concern, and scores above 15 indicate an environment that may not be suitable for sensitive occupants without remediation. These thresholds originate from clinical observation rather than large-scale epidemiological validation, so they function as guidelines rather than absolute cutoffs. Context matters: a score interpreted alongside biomarkers, symptom patterns, and a physical building inspection provides a more complete assessment than the number alone.

For a baseline assessment of a new home or office, a single ERMI or HERTSMI-2 test is typically sufficient. Retesting is warranted after any remediation work to confirm that mold levels have decreased to acceptable thresholds. If an individual is undergoing treatment for mold-related illness, post-remediation testing serves as a checkpoint before resuming occupancy or beginning certain treatment protocols that require a clean environment.

In buildings with a history of water intrusion or in climates with high humidity, periodic retesting every 12 to 24 months can detect new contamination before it becomes extensive. Any new water event, whether from flooding, roof leaks, or plumbing failures, should prompt retesting once the area has been dried and repaired. Routine annual testing is generally unnecessary in buildings without water damage history or prior elevated scores.

The ERMI scoring system was developed by the U.S. Environmental Protection Agency (EPA) using MSQPCR technology and validated against a national database of dust samples from approximately 1,100 homes. Epidemiological studies have correlated higher ERMI scores with increased rates of asthma and respiratory illness in children, providing population-level support for the index as a health-relevant metric. The HERTSMI-2 panel was developed in clinical practice by physicians treating CIRS, with thresholds derived from observational data on patient outcomes in different mold environments.

That said, several limitations deserve attention. Neither test has been validated through large randomized controlled trials as a clinical diagnostic tool. ERMI scores can vary depending on sampling location within a building, how recently floors were cleaned, and whether carpeting is present. The EPA itself has stated that ERMI was designed as a research tool and not intended as a standalone basis for remediation decisions. HERTSMI-2 thresholds, while clinically useful in practice, are based on a relatively small body of observational data and have not been independently replicated at scale. Despite these caveats, both tests remain among the most specific tools available for quantifying species-level mold contamination in indoor environments.

False reassurance is the primary risk: a low ERMI or HERTSMI-2 score does not guarantee a mold-free environment, because sampling location, recent cleaning, and the specific species panel may miss localized contamination in wall cavities or HVAC ducts. Conversely, elevated scores can cause significant anxiety and prompt costly remediation that may not be necessary if the species detected are not actively growing or producing mycotoxins. Results should be interpreted in clinical context, ideally alongside biomarker testing and symptom assessment, and major remediation decisions are best guided by a qualified environmental professional who can physically inspect the building.